Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Literature
1.
Pineles SL, Liu GT, Acebes X et al (2011) Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J Neuroophthalmol 31(3):217–223CrossRefPubMed
2.
Hervier B, Haroche J, Arnaud L et al (2014) Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124(7):1119–1126CrossRefPubMed
3.
Emile JF, Abla O, Fraitag S et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127(22):2672–2681CrossRefPubMedPubMedCentral
4.
Diamond EL, Durham BH, Haroche J et al (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6(2):154–165CrossRefPubMed
5.
Badalian-Very G (2014) A common progenitor cell in LCH and ECD Blood 124(7):991–992PubMed
6.
WnorowskI M, Prosch H, Prayer D et al (2008) Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr 153(1):127–132CrossRefPubMed
7.
8.
Bhatia A, Hatzoglou V, Ulaner G et al (2020) Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro Oncol 22(7):979–992CrossRefPubMedPubMedCentral
9.
Lambeck J, Hieber M, Dreßing A, Niesen W-D (2019) Central pontine myelinosis and osmotic demyelination syndrome. Dtsch Arztebl Int 116(35–36):600–606PubMed
10.
Berkman J, Ford C, Johnson E et al (2018) Misdiagnosis: CNS Erdheim-Chester disease mimicking CLIPPERS. Neuroradiol J 31(4):399–402CrossRefPubMed
Metadata
Title
Preceding polydipsia/polyuria, ataxia, and dysarthria in an adult with mixed histiocytosis (Erdheim Chester disease/Langerhans cell histiocytosis)
Authors
Takashi Miyoshi
Shigehisa Tamaki
Ko Kudo
Fumihiko Kono
Tomoya Masada
Shinsaku Imashuku
Publication date
05-10-2022
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04998-2

Other articles of this Issue 12/2022

Annals of Hematology 12/2022 Go to the issue

Letter to the Editor

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience

Letter to the Editor

Hemoglobin Beth Israel [HBB:c.308A>G (p.Asn103Ser)]: an ultra-rare, low oxygen-affinity, non-methemoglobinemic hemoglobin diagnosed on targeted resequencing as cause of dominantly inherited benign cyanosis

Original Article

Monitoring energy balance through clinical and serum biomarkers in patients with hematologic malignancies undergoing chemotherapy

Original Article

Clinical and prognostic role of 2-[18F]FDG PET/CT and sarcopenia in treatment-naïve patients with T-cell lymphoblastic lymphoma

Original Article

Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels

Original Article

Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits